Asbestos and Talc Lawsuit Update 2026

Seven months into 2026, one thing is clear: predictions that asbestos litigation would fade into history remain premature — even as the single largest piece of it moves toward resolution. On July 27, Johnson & Johnson announced a proposed settlement of the ovarian talc docket estimated at $5.5 billion. But filings are still climbing, the mesothelioma docket is untouched by the deal, the largest single-plaintiff talc verdict on record is still working its way through post-trial motions, and the regulatory framework governing future exposure sits with the Fifth Circuit. Below is a mid-year snapshot of the developments practitioners, insurers, and claimants should have on their radar.

The headline: J&J's proposed $5.5 billion ovarian talc resolution

On July 27, J&J announced an agreement with the plaintiff firms leading the federal MDL and related state proceedings to resolve the remaining ovarian talc litigation. Reuters reported the estimated value at $5.5 billion, covering roughly 76,000 claims — those consolidated in the District of New Jersey plus related state court cases — and representing nearly all remaining talc claims against the company. The Wall Street Journal framed the figure as a ceiling of up to $5.5 billion; plaintiffs' leadership describes the structure differently, and the distinction matters.

The terms practitioners should note:

• Participation threshold. The deal is conditioned on express participation by lead plaintiff firms representing at least 95% of the remaining claims. Until that threshold is met, nothing is final.
• Uncapped, grid-based. Chris Seeger, who helped negotiate the agreement, told Reuters the settlement assigns values to qualifying ovarian claims through a tiered grid but does not cap J&J's total payout — and that the company could ultimately pay $7 billion or more depending on enrollment. Plaintiffs' firms describe it as an uncapped fund rather than a fixed pot divided among participants.
• Payment timing. J&J expects to pay roughly $3 billion in 2027, with further payments in 2028. Seeger has said claims should be paid within about 18 months — a sharp contrast to the decade-plus payout schedules contemplated in the rejected bankruptcy plans.
• Existing claims only. Unlike the prepackaged Chapter 11 proposals, this agreement resolves only currently pending claims. It creates no channeling injunction and no trust for future claimants. Anyone diagnosed tomorrow retains a cause of action.
• Ovarian only. The deal addresses ovarian cancer claims. J&J says it has separately resolved roughly 95% of filed mesothelioma suits, all state consumer protection claims, and all talc-supplier disputes.

The framing from each side is predictably opposed. J&J's worldwide vice president of litigation, Erik Haas, called the claims meritless and said the company was confident it would have prevailed, characterizing the settlement as a way to put the matter behind it. Plaintiffs' firms have called it a good resolution after a decade-long fight. Bloomberg Law noted that J&J had reserved $11 billion for talc matters as of June, and that Bloomberg Intelligence analysts had modeled $10–12 billion in eventual settlement costs — context that makes $5.5 billion look, from the company's side, like a favorable outcome.

What broke the logjam: the specific-causation order

The settlement did not arrive out of nowhere. It followed a July 22 ruling by U.S. Magistrate Judge Rukhsanah Singh in Trenton that cast serious doubt on approximately 69,000 MDL claims. Two of plaintiffs' specific-causation experts, Judith Wolf and Daniel Clarke-Pearson, testified in May in preparation for a set of six bellwether trials and acknowledged they could not entirely rule out other causes of a given plaintiff's ovarian cancer. Judge Singh wrote that if that uncertainty reflects reality, it was unclear how any individual plaintiff could carry her burden. She stopped short of immediate dismissal, instead issuing an order to show cause and directing plaintiffs to respond by November 19 explaining why their cases should not be dismissed for want of an admissible specific-causation opinion.

The doctrinal shape of this is worth dwelling on. Six months earlier, plaintiffs had won the general causation fight (see below). The litigation then foundered on specific causation — the individualized question of whether talc caused this claimant's disease. That is a familiar failure mode in toxic tort litigation with relative risks near the margin, and it is the structural reason a docket that looked robust in January was settling in July.

Filings are up, and talc is driving the change

KCIC's 2025 Asbestos Litigation: Year in Review, released in April 2026, remains the closest thing the field has to a national registry, capturing roughly 90% of asbestos-related personal injury complaints filed in the United States. The 2025 data show total filings back at pre-pandemic levels, rising for a third consecutive year, with mesothelioma and lung cancer continuing to account for roughly half and 40% of complaints, respectively.

The most striking trend is talc. Talc-related filings jumped sharply year over year, and as KCIC's analysts noted at the DRI Asbestos Medicine conference, talc exposure is now alleged in more than 40% of mesothelioma complaints — up from under 5% a decade ago — with roughly 90% of talc trials over the past five years decided for plaintiffs. Jurisdictionally, the familiar leaders (Madison and St. Clair Counties in Illinois, New York City, Philadelphia) held their positions, though coverage of the KCIC report notes momentum shifting toward New York and Philadelphia, and an August 2025 Illinois statute expanding that state's courts' ability to hear asbestos cases may concentrate filings further.

Note that these filing trends are largely unaffected by the July settlement. Because the deal reaches only pending claims, and because the mesothelioma docket is separate, the filing pipeline continues.

The trial record that produced the settlement

The defining structural event of this litigation cycle was Judge Christopher Lopez's March 31, 2025 dismissal of Red River Talc LLC's prepackaged Chapter 11 — J&J's third and, the company has said, final attempt to channel its talc liabilities through bankruptcy. As Bloomberg Law reported, the court found the proposed multibillion-dollar plan foundered on solicitation and voting irregularities and on third-party release architecture that could not survive Fifth Circuit precedent. J&J announced it would not appeal or refile, returning tens of thousands of claims to the tort system.

The consequences of a full return to jury trials showed up quickly and dramatically. The headline verdict came in December 2025, when a Baltimore jury awarded more than $1.5 billion — $59.84 million compensatory plus $1.5 billion punitive — to Cherie Craft, a Maryland woman with peritoneal mesothelioma attributed to lifelong use of Johnson's Baby Powder, widely reported as the largest single-plaintiff talc award to date. Days earlier, a Ramsey County, Minnesota jury returned $65.5 million for a 37-year-old mother of three with mesothelioma linked to childhood talc use, as the Associated Press reported, and a Los Angeles jury awarded $40 million to two ovarian cancer plaintiffs — a verdict J&J immediately vowed to appeal, per Reuters.

Plaintiffs have not had it all their way. In March 2026, a Los Angeles judge struck the $950 million punitive component of the October 2025 verdict for the family of Mae Moore — originally $966 million, among the largest talc awards ever — finding the punitive-damages standard unmet while leaving the jury's causation finding and $16 million in compensatory damages intact, Law.com reported. And June brought a split screen in Los Angeles: a jury awarded $32 million to the family of Maria Lozano in a baby-powder mesothelioma trial just two days after a different jury returned a defense verdict in a coordinated ovarian cancer case.

Reuters reports that J&J came to the settlement table after a run of favorable developments: individual trial wins, successful efforts to disqualify plaintiffs' counsel, and adverse rulings against plaintiffs' experts. Note what the settlement does not touch: the Craft verdict and other mesothelioma awards sit outside the ovarian resolution, and post-trial and appellate practice on those continues.

The MDL's second Daubert round went (mostly) to plaintiffs — on general causation

The most consequential pretrial ruling of the first half of the year came on January 20, 2026, when retired U.S. District Judge Freda Wolfson — who presided over the federal ovarian cancer MDL (MDL 2738, D.N.J.) from 2016 until her 2023 retirement and now serves as special master — issued a 658-page Report and Recommendation to Judge Michael Shipp resolving renewed Rule 702 motions brought after the 2023 amendments to the federal expert-evidence rule. As a detailed analysis in the National Law Review explains, Judge Wolfson largely reaffirmed her 2020 rulings and recommended that most of the roughly 39 proffered experts on both sides be permitted to testify — including plaintiffs' epidemiologists offering the opinion that genital talc use is associated with ovarian cancer — while trimming certain opinions, such as portions of materials scientist Dr. William Longo's PLM-based asbestos findings.

That ruling cleared general causation and moved the MDL toward bellwether trials. It was the specific-causation record developed in preparation for those bellwethers that produced Judge Singh's July order — and, within days, the settlement. For practitioners in other mass torts, the sequence is the lesson: clearing Rule 702 on general causation is necessary but nowhere near sufficient.

The Lancet retracts a 49-year-old talc commentary

Science and litigation collided in March, when The Lancet retracted an unsigned 1977 commentary that had concluded normal consumer exposure to cosmetic talc posed no cancer hazard. Public health historians David Rosner (Columbia) and Gerald Markowitz (John Jay College) traced the anonymous piece to Francis J.C. Roe, a paid J&J consultant who, corporate discovery documents show, shared an advance draft with the company and revised it based on its feedback. The journal's editors called the undisclosed relationship a clear breach of publishing ethics. As Retraction Watch reported, the commentary had been cited for decades in talc defense arguments; J&J disputes that the episode reflects misconduct.

With the ovarian docket settling, the retraction's near-term litigation value shifts to the continuing mesothelioma trials and to whatever future ovarian claims are filed outside the settlement.

Beyond talc: a landmark premises ruling on the traditional docket

The traditional occupational docket produced the year's most significant state supreme court decision. In Estate of Lorbiecki v. Pabst Brewing Co., 2026 WI 12 (Apr. 15, 2026), the Wisconsin Supreme Court held 5–2 that Pabst could be liable under Wisconsin's safe-place statute for the mesothelioma death of Gerald Lorbiecki, a union steamfitter employed by an independent contractor who cut out asbestos-insulated pipe at the Milwaukee brewery in the 1970s, USA TODAY Network reported. As the State Bar of Wisconsin's case review explains, the court concluded the statute's protections extend to "frequenters," including contractors' employees, where the owner knew of the asbestos hazard — while also recalculating the punitive-damages cap against Pabst's apportioned share of compensatory damages, yielding a final judgment of roughly $7 million. The decision meaningfully strengthens premises-liability theories against property owners in Wisconsin and will be studied in safe-place and frequenter-doctrine jurisdictions elsewhere.

Regulatory backdrop: the chrysotile ban's fate rests with the Fifth Circuit

On the regulatory side, EPA's March 2024 rule banning ongoing uses of chrysotile asbestos — the first risk-management rule finalized under the amended Toxic Substances Control Act — spent 2025 on a rollercoaster. The agency signaled in mid-2025 that it would reconsider the rule, a plan it subsequently abandoned, and the consolidated industry and public-health challenges proceeded, as chronicled in the Asbestos Disease Awareness Organization's litigation timeline. Texas Chemistry Council v. EPA (5th Cir. No. 24-60193) was argued on June 1, 2026 — before the same circuit that vacated EPA's 1989 asbestos ban in Corrosion Proof Fittings — and a ruling is pending, with the rule's phase-out deadlines (including the chlor-alkali industry's transition window) remaining in effect in the meantime. Whatever the outcome, the decision will shape future exposure patterns and, decades from now, the tail of this litigation.

The scientific literature courts are reading

The renewed Daubert fight has put recent epidemiology at the center of the docket. Chief among the post-2020 studies is O'Brien et al., Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis, J. Clin. Oncol. 42:2645–2659 (2024), an NIEHS-funded analysis of the 50,884-woman Sister Study cohort that found genital talc use positively associated with ovarian cancer even after modeling recall bias and exposure misclassification — a consistent association, as the lead author put it. An accompanying JCO editorial situates the finding within pooled case-control analyses showing elevated risk among ever-users of genital powder.

That literature was strong enough to clear general causation before Judge Wolfson and too thin, in Judge Singh's view, to carry individual claimants across the specific-causation line. Defendants continue to contest causation vigorously, and the settlement does not resolve the scientific question — it prices it.

What to watch in the second half of 2026

• Whether the 95% threshold is met. Firms that believe their inventories are worth more than the grid provides may hold out. Watch enrollment through the fall.
• The November 19 show-cause deadline. If the settlement falters, Judge Singh's order becomes live again, and the downside case for plaintiffs is severe.
• The mesothelioma docket. Post-trial motions in Craft, appellate practice on the Los Angeles verdicts, and continuing trials in Philadelphia, Madison County, and New York.
• The Fifth Circuit in Texas Chemistry Council.
• Future-claim exposure. With no channeling injunction, J&J's talc liability tail is capped only by the statute of limitations and the latency period. This is a resolution of a docket, not of a liability.

‍

‍